She discusses the current state of evidence on the role of fluid and neurophysiological biomarkers in the early diagnosis of progression of relapsing-remitting MS to secondary progressive MS, and more.
...
She discusses the current state of evidence on the role of fluid and neurophysiological biomarkers in the early diagnosis of progression of relapsing-remitting MS to secondary progressive MS, and more.
...
She discusses the current state of evidence on the role of fluid and neurophysiological biomarkers in the early diagnosis of progression of relapsing-remitting MS to secondary progressive MS, and more.
...
He talks about his session at our Advances in Inflammatory Bowel Disease regional meeting in Los Angeles, during which he will speak about the importance of dysplasia surveillance and how dysplasia should...
He talks about his session at our Advances in Inflammatory Bowel Disease regional meeting in Los Angeles, during which he will speak about the importance of dysplasia surveillance and how dysplasia should...
He talks about his session at our Advances in Inflammatory Bowel Disease regional meeting in Los Angeles, during which he will speak about the importance of dysplasia surveillance and how dysplasia should...
He talks about his session at our Advances in Inflammatory Bowel Disease regional meeting in Los Angeles, during which he will speak about the importance of dysplasia surveillance and how dysplasia should...
David Holtzman, MD, talks about the established biomarkers for Alzheimer disease, potential biomarkers being investigated, and how long it may take for these biomarker tests to make it to the bedside.
David Holtzman, MD, talks about the established biomarkers for Alzheimer disease, potential biomarkers being investigated, and how long it may take for these biomarker tests to make it to the bedside.
In this podcast, Christina Y. Ha, MD, provides insight into the prevention and management of Clostridioides difficile infection among patients with inflammatory bowel disease. It is a topic she will be...
